Quantcast
Last updated on April 21, 2014 at 9:29 EDT

Latest Placebo-controlled study Stories

2013-12-08 08:22:17

NEW ORLEANS, Dec. 8, 2013 /PRNewswire-USNewswire/ -- A series of studies presented today during the 55th American Society of Hematology Annual Meeting and Exposition in New Orleans uncover promising efficacy and safety results for several unique compounds and combination treatments, each aimed at improving long-term outcomes for patients with blood disorders ranging from clots to cancer. Recent advances have helped hematologists better understand the cellular activity of blood...

2013-12-05 20:22:00

LEXINGTON, Massachusetts, December 5, 2013 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, today announced top-line results from OPUS-2, a Phase 3 efficacy and safety study of 5.0% lifitegrast ophthalmic solution. OPUS-2 compared lifitegrast to placebo administered twice daily for 84 days (12 weeks) in dry eye patients with history of active artificial tear use within 30 days prior to screening. Lifitegrast met the...

2013-12-05 08:28:48

IRVINE, Calif., Dec. 5, 2013 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of...

2013-11-18 08:28:30

- Confirms results of phase II studies, with consistent virologic response and tolerability profile NORTH CHICAGO, Ill., Nov. 18, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) released the first phase III results for the investigational three direct-acting-antiviral (3D) regimen plus ribavirin in patients chronically infected with genotype 1 (GT1) hepatitis C virus (HCV). In the 631-patient SAPPHIRE-I study, patients new to therapy receiving 12 weeks of AbbVie's 3D regimen achieved...

2013-11-04 08:27:28

RYE, N.Y., Nov. 4, 2013 /PRNewswire/ -- Curemark LLC announced that it has begun the rolling submission of a New Drug Application (NDA) for CM-AT, the company's autism treatment, with the U.S. Food and Drug Administration. CM-AT had previously been granted Fast Track status by the FDA, a designation given to drug candidates that treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs. The rolling submission process allows companies...

2013-10-08 08:30:09

RYE, N.Y., Oct. 8, 2013 /PRNewswire/ -- Curemark LLC announced today the closing of $18.5 million in common equity financing led by a leading European institutional investor. Curemark will use the funds for the completion and filing requirements for its New Drug Application (NDA) for CM-AT, the company's autism treatment, and the development of the other therapies in its pipeline. "The completion of our latest financing allows us to determine the commercial pathway for CM-AT to...

2013-09-24 04:22:04

Clinical Trial Shows Compound Not Only Helped Study Subjects Lose Weight, but Drop Actual Body Fat from Hips, Waist, Thighs, and Butt NEW YORK, Sept. 24, 2013 /PRNewswire/ -- The highly respected British Journal of Nutrition published the results of a randomized, double-blind, placebo-controlled clinical trial on a compound many are calling a "miracle pill." The clinical trial showed that this compound not only helped study subjects lose weight, but actually reshape their entire...

2013-09-09 16:24:06

Company To Host Conference Call And Webcast Monday, September 9th At 5:00PM ET / 2:00PM PT SAN DIEGO, Sept. 9, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the 50mg dose of NBI-98854, a small molecule VMAT2 inhibitor in development for tardive dyskinesia, did not meet the primary endpoint in the Phase IIb Kinect study while the 100mg dose showed a statistical and clinically significant improvement. The pre-specified primary endpoint was the...

2013-08-21 16:24:49

OSAKA, Japan, Aug. 21, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") today announced that results from two Phase 3 studies evaluating vedolizumab, an investigational humanized monoclonal antibody, for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD), were published in the August 22, 2013 issue of the New England Journal of Medicine. Chronic and debilitating diseases, CD and UC are the two most common...

2013-08-01 14:37:49

In an editorial published online today in BMJ, bioethicist Jeremy Sugarman and other experts warn that action is urgently needed to deal with possible unintended consequences of India’s new policy to protect research participants. Passed earlier this year, the Drugs and Cosmetics Act (First Amendment) Rules, was meant to mitigate ethical concerns with potential serious consequences for public health, as well as India’s viability as a continued global...